CLINICAL_TRIALS
trial_result
· 2024-05-09
Clinical Trial Update: Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome [Phase 2]
Summary
A Phase 2 clinical trial evaluating inhibition of reverse transcription in Aicardi-Goutières Syndrome has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: University of Edinburgh | Conditions: Aicardi-Goutières Syndrome | Phase 2 | Status: COMPLETED